Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17280207 | 0.81 | GRK6 (0.46) | GRK6CTSSCTSK | |
| SCHEMBL17280099 | 0.79 | GRK6 (0.48) | BRD4SYKGRK6KMT2AALDH1A1 | |
| SCHEMBL17279971 | 0.77 | BRD4 (0.46) | BRD4SYKTNNI3KCYP3A4KMT2A | |
| SCHEMBL17280220 | 0.71 | ALDH1A1 (0.47) | CYP3A4KMT2AALDH1A1 | |
| SCHEMBL17280174 | 0.71 | METAP2 (0.41) | KMT2ACTSSCTSKALDH1A1SMN1; SMN2 | |
| SCHEMBL17279786 | 0.70 | MEN1 (0.46) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13595012 | 0.70 | GBA1 (0.56) | BRD4KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17279780 | 0.69 | MEN1 (0.43) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL350324 | 0.68 | KMT2A (0.77) | KMT2AALDH1A1 | |
| SCHEMBL31404044 | 0.68 | KMT2A (0.77) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020149206-A1 | METHOD FOR PRODUCING ACRYLIC RESIN FILM | コニカミノルタ株式会社 | 2020-07-23 | — | — | WO | disclosed |
| US-20180203175-A1 | TRIAZOLE COMPOUND | Konica Minolta, Inc. (JP) | 2018-07-19 | — | — | US | disclosed |
| US-20180203175-A1 | TRIAZOLE COMPOUND | Konica Minolta, Inc. (JP) | 2018-07-19 | — | — | US | disclosed |
| US-10012777-B2 | Resin composition | Konica Minolta, Inc. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10012777-B2 | Resin composition | Konica Minolta, Inc. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20150338563-A1 | RESIN COMPOSITION, TRIAZOLE COMPOUND, OPTICAL FILM, POLARIZING PLATE, OPTICAL LENS, CIRCULARLY POLARIZING PLATE AND IMAGE DISPLAY DEVICE | KONICA MINOLTA, INC (JP) | 2015-11-26 | — | — | US | disclosed |
| US-20150338563-A1 | RESIN COMPOSITION, TRIAZOLE COMPOUND, OPTICAL FILM, POLARIZING PLATE, OPTICAL LENS, CIRCULARLY POLARIZING PLATE AND IMAGE DISPLAY DEVICE | KONICA MINOLTA, INC (JP) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150338563-A1 | RESIN COMPOSITION, TRIAZOLE COMPOUND, OPTICAL FILM, POLARIZING PLATE, OPTICAL LENS, CIRCULARLY POLARIZING PLATE AND IMAGE DISPLAY DEVICE | HRH3, HELZ, NBAS | BRD4 691/4885SYK 3566/4885TDO2 791/4885 |
| US-10012777-B2 | Resin composition | NBAS, WDR5, HRH3 | BRD4 526/4885SYK 3757/4885TDO2 1362/4885 |
| US-20180203175-A1 | TRIAZOLE COMPOUND | H1-10, TTI2, H1-2 | BRD4 36/4885SYK 1324/4885TDO2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.